Jared Moskowitz
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
4 flagsJared Moskowitz sold $15,001-$50,000 in $PEP on 2025-12-02, 15 days before HR6832, the "PACK Act," was introduced, which could increase compliance costs for consumer packaged goods manufacturers.
Jared Moskowitz sold $15,001-$50,000 in $PEP on 2025-12-02, 71 days before HR7502 was introduced, proposing a federal standard for 'recycled content' claims that could increase compliance costs.
Jared Moskowitz bought $1,001-$15,000 in SO on 2025-12-02, 50 days before HR161, the "New Source Review Permitting Improvement Act," was introduced, which could reduce environmental permitting burdens for industrial facilities.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $ATO | Atmos Energy Corporation Common Stock | $1K-$15K | $170.08 | — | — | Dec 2, 2025 |
| BUY | $MCK | McKesson Corporation Common Stock | $1K-$15K | $829.70 | — | — | Dec 2, 2025 |
| BUY | $MCK | McKesson Corporation Common Stock | $1K-$15K | $829.70 | — | — | Dec 2, 2025 |
| BUY | $PEG | Public Service Enterprise Group Incorporated Common Stock | $1K-$15K | $80.68 | — | — | Dec 2, 2025 |
| BUY | $SO | Southern Company | $1K-$15K | $89.04 | — | — | Dec 2, 2025 |
| SELL | $PEP | Pepsico, Inc. | $15K-$50K | $148.61 | $153.21 | +3.1% | Dec 2, 2025 |
| SELL | $PEP | Pepsico, Inc. | $1K-$15K | $148.61 | $153.21 | +3.1% | Dec 2, 2025 |
| SELL | $PEP | Pepsico, Inc. | $1K-$15K | $148.61 | $153.21 | +3.1% | Dec 2, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
MEDLINE INDUSTRIES, LP: $77.6M Department of Veterans Affairs Contract
Medline Industries, a private company, secured a $77.6 million contract from the Department of Veterans Affairs for medical-surgical supplies. This contract highlights ongoing government demand for healthcare provisions, indirectly benefiting publicly traded medical supply distributors and healthcare service providers.
Clean Water Justice Act
HR 6616 (Clean Water Justice Act) proposes a 400% increase in maximum criminal fines for Clean Water Act violations but remains in early legislative stages (referred to subcommittee). The bill carries no direct spending or revenue, and current market prices for affected tickers show no correlation to this procedural event. Immediate market impact is negligible.
To prohibit a person from making a misleading recycled content claim in advertising, marketing, selling, or offering for sale a product to a consumer, and for other purposes.
HR7502 proposes a federal standard prohibiting misleading recycled content claims in consumer product marketing. The bill is in early committee stage with 9 cosponsors and limited legislative momentum. For $PG, $KO, $PEP, $KMB, and $CL, the bill imposes added compliance costs with no revenue offset — structurally bearish but low probability of passage in current form.
To amend the Federal Trade Commission Act to include requirements for recyclable, compostable, and reusable claims for packaging for a consumer product, and for other purposes.
The PACK Act (HR6832) introduces new regulatory burdens for consumer packaged goods manufacturers by establishing strict requirements for recyclable, compostable, and reusable claims on product packaging. This bill, currently in the early stages of the legislative process, creates compliance costs for companies like Procter & Gamble, Coca-Cola, and PepsiCo. Recent market data shows mixed performance for these companies, with some experiencing gains and others declines over the past 7 and 30 days.
New Source Review Permitting Improvement Act
HR161 (New Source Review Permitting Improvement Act) reported out of House Energy & Commerce Committee on April 28, 2026. Refiners ($MPC, $PSX) and chemical companies ($LYB, $DOW) show strong 7-day gains of +9.37% and +8.75% respectively, reflecting market pricing of regulatory relief. The bill redefines NSR 'modification' to require a 10-year peak-hourly baseline and exempts reliability/safety projects, directly lowering compliance costs for heavy industry.
Honduras Expropriation Accountability Act
HR 7807 is an early-stage procedural bill authorizing a claims commission for U.S. persons with expropriated property in Honduras. It allocates no funding and has no market impact on any publicly traded company. Recent moves in $KO, $PEP, $ADM, $XOM, $CVX are driven by earnings and commodity prices, not this legislation.
PBM Kickback Prohibition Act
HR7895 is an early-stage House bill banning referral compensation to PBMs. It has no Senate companion, sits at the start of the legislative process, and has near-zero passage probability in this Congress. Market data shows the three largest PBM-associated stocks (CVS, UNH, CI) have rallied significantly over the past 30 days — this bill is not a driver of those moves. The bill's impact, if enacted, would be immaterial to all three companies' financials.
TVA IRP Act
The TVA IRP Act (HR6357) is an early-stage procedural bill that applies directly to TVA but establishes a template for state regulators. No funding is authorized. Market impact is negligible for the near term — the bill has a long legislative path and no current mechanism to bind investor-owned utilities. Real market data shows Southern Company ($SO) at $96.21 and Duke Energy ($DUK) at $129.07 both near the top of their 52-week ranges, with modest weekly gains of +2.91% and +1.41% respectively, reflecting no material concern from this procedural bill.
To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.
HR7877 (Shane DiGiovanna Act) mandates a 2-year nationwide Medicaid demonstration program covering wound care and OTC drugs for epidermolysis bullosa. The bill is in early legislative stages (referred to committee, 5 cosponsors) with no explicit funding authorized. Market impact is minimal — the affected patient population is small (~3,000-5,000 individuals), and near-term passage is uncertain.
Data Center Transparency Act
The Data Center Transparency Act (HR6984) is an early-stage bill requiring extensive quarterly and semi-annual public reporting on data center water use, energy consumption, and emissions. This introduces new compliance costs for data center REITs like $EQIX and $DLR without direct revenue offset, while utilities ($DUK, $SO, $NEE) face enhanced scrutiny on load growth disclosures. The bill is in a procedural early stage — referred to committee with 4 cosponsors — so near-term market impact is muted, but investors should monitor committee markup for potential expansion to permit moratoria or efficiency standards.
Other Filings by Jared Moskowitz
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.